Markus Chmielewski

5.0k citations
38 papers · 4.0k · 1 hit paper · h-index 30

Impact in

  • Oncology top 0.5%
    • CAR-T cell therapy research
    • Cancer Immunotherapy and Biomarkers
  • Immunology top 1%
    • Immune Cell Function and Interaction
    • Immunotherapy and Immune Responses
    • T-cell and B-cell Immunology

Papers in

  • Oncology 33
    • CAR-T cell therapy research 33
    • Cancer Immunotherapy and Biomarkers 2
  • Immunology 27
    • Immune Cell Function and Interaction 19
    • T-cell and B-cell Immunology 11
    • Immunotherapy and Immune Responses 10
Co-authors
Hinrich Abken (35 shared papers)Andreas Hombach (13 shared papers)Gunter Rappl (6 shared papers)Tobias Riët (4 shared papers)Claudia Heuser (1 shared paper)Gregory P. Adams (1 shared paper)Rolf Kiessling (2 shared papers)Felix Bohne (2 shared papers)
Journals
Molecular Therapy (4 papers)Frontiers in Immunology (4 papers)Gastroenterology (4 papers)OncoImmunology (3 papers)The Journal of Immunology (2 papers)
Partner nations
GermanyUnited StatesFrance

In The Last Decade

Markus Chmielewski

38 papers receiving 4.0k citations

Markus Chmielewski's Hit Papers

TRUCKs: the fourth generation of CARs 2015 · 563 citations
5630+3+7Years since publication100200300400500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2015 Expert Opinion on Biological Therapy

Peers

Markus Chmielewski
Comparison fields: 5 of 88
  • Oncology 3.5k
  • Immunology 1.7k
  • Genetics 1.0k
  • Biomedical Engineering 1.2k
  • Hepatology 138
Replace Mio Kitano with:
Mio Kitano United States
Sid P. Kerkar United States
Andreas Hombach Germany
Joseph A. Fraietta United States
Meng-Fen Wu United States
David E. Gilham United Kingdom
Leonid Cherkassky United States
Andrew Kaiser Germany
April Durett United States
Dhanalakshmi Chinnasamy United States
Markus Chmielewski relative to Mio Kitano United States Mio Kitano's profile →
Citations per field
00.5×2×3.4×
Mio Kitano · 1×
Citations per year

Countries citing papers authored by Markus Chmielewski

Since Specialization
Citations

This map shows the geographic impact of Markus Chmielewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Chmielewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Chmielewski more than expected).

Fields of papers citing papers by Markus Chmielewski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Chmielewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Chmielewski. The network helps show where Markus Chmielewski may publish in the future.

Co-authors

The 25 scholars most cited alongside Markus Chmielewski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Markus Chmielewski Line = papers co-authored together Markus Chmielewski links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#Work
1
TRUCKs: the fourth generation of CARs
Expert Opinion on Biological Therapy ·Markus Chmielewski, Hinrich Abken
Hit paper breakdown →		2015563
2
IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
Cancer Research ·Markus Chmielewski, Caroline Kopecky, Andreas Hombach, Hinrich Abken
2011446
3
CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors
Cell Reports ·Markus Chmielewski, Hinrich Abken
2017332
4
Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
Immunological Reviews ·Markus Chmielewski, Andreas Hombach, Hinrich Abken
2013291
5
T Cell Activation by Antibody-Like Immunoreceptors: Increase in Affinity of the Single-Chain Fragment Domain above Threshold Does Not Increase T Cell Activation against Antigen-Positive Target Cells but Decreases Selectivity
The Journal of Immunology ·Markus Chmielewski, Andreas Hombach, Claudia Heuser, Gregory P. Adams, Hinrich Abken
2004205
6
Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor Activity
The Journal of Immunology ·Maarten A. Ligtenberg, Dimitrios Mougiakakos, Madhura Mukhopadhyay, Kristina Witt, Álvaro Lladser, Markus Chmielewski, Tobias Riët, Hinrich Abken, Rolf Kiessling
2015177
7
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+T cells
OncoImmunology ·Andreas Hombach, Johannes Heiders, Marcel Foppe, Markus Chmielewski, Hinrich Abken
2012167
8
T Cells Expressing a Chimeric Antigen Receptor That Binds Hepatitis B Virus Envelope Proteins Control Virus Replication in Mice
Gastroenterology ·K. Krebs, Nina Böttinger, Li–Rung Huang, Markus Chmielewski, Silke Arzberger, Georg Gasteiger, Clemens Jäger, Edgar Schmitt, Felix Bohne, Michaela Aichler, Wolfgang Uckert, Hinrich Abken, Mathias Heikenwälder, Percy A. Knolle, Ulrike Protzer
2013167
9
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Proceedings of the National Academy of Sciences ·Anna Kruschinski, Andreas Moosmann, Isabel Poschke, Håkan Norell, Markus Chmielewski, Barbara Seliger, Rolf Kiessling, Thomas Blankenstein, Hinrich Abken, Jehad Charo
2008158
10
T Cells Redirected Against Hepatitis B Virus Surface Proteins Eliminate Infected Hepatocytes
Gastroenterology ·Felix Bohne, Markus Chmielewski, Gregor Ebert, Katja Wiegmann, Timo Kürschner, Andreas Schulze, Stephan Urban, Martin Krönke, Hinrich Abken, Ulrike Protzer
2008135
11
TRUCKS, the fourth‐generation CAR T cells: Current developments and clinical translation
University of Regensburg Publication Server (University of Regensburg) ·Markus Chmielewski, Hinrich Abken
2020128
12
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells
Frontiers in Immunology ·Markus Chmielewski, Andreas Hombach, Hinrich Abken
2013124
13
T Cells That Target Carcinoembryonic Antigen Eradicate Orthotopic Pancreatic Carcinomas Without Inducing Autoimmune Colitis in Mice
Gastroenterology ·Markus Chmielewski, Olga Hahn, Gunter Rappl, Michael Nowak, Ingo H. Schmidt–Wolf, Andreas Hombach, Hinrich Abken
2012114
14
CD28 Costimulation Impairs the Efficacy of a Redirected T-cell Antitumor Attack in the Presence of Regulatory T cells Which Can Be Overcome by Preventing Lck Activation
Molecular Therapy ·David M. Kofler, Markus Chmielewski, Gunter Rappl, Anja Hombach, Tobias Riët, Annette Schmidt, Andreas Hombach, Clemens‐Martin Wendtner, Hinrich Abken
2011108
15
CAR T cells transform to trucks: chimeric antigen receptor–redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer
Cancer Immunology Immunotherapy ·Markus Chmielewski, Hinrich Abken
201297
16
Redirected T Cells That Target Pancreatic Adenocarcinoma Antigens Eliminate Tumors and Metastases in Mice
Gastroenterology ·Amit Maliar, Charlotte Servais, Tova Waks, Markus Chmielewski, Ron Lavy, Peter Altevogt, Hinrich Abken, Zelig Eshhar
201286
17
Chimeric Antigen Receptor-Redirected Regulatory T Cells Suppress Experimental Allergic Airway Inflammation, a Model of Asthma
Frontiers in Immunology ·Jelena Škuljec, Markus Chmielewski, Christine Happle, Anika Habener, Mandy Busse, Hinrich Abken, Gesine Hansen
201786
18
Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors
OncoImmunology ·André Kunert, Markus Chmielewski, Rebecca Wijers, Cor Berrevoets, Hinrich Abken, Reno Debets
201778
19
Superior Therapeutic Index in Lymphoma Therapy: CD30+ CD34+ Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack
Molecular Therapy ·Andreas Hombach, André Görgens, Markus Chmielewski, Florian Murke, Janine Kimpel, Bernd Giebel, Hinrich Abken
201665
20
Efficacy of CAR T-cell Therapy in Large Tumors Relies upon Stromal Targeting by IFNγ
Cancer Research ·Ana Textor, Joanna J. Listopad, Lara Le Wührmann, Cynthia Pérez, Anna Kruschinski, Markus Chmielewski, Hinrich Abken, Thomas Blankenstein, Jehad Charo
201458

About Markus Chmielewski

Markus Chmielewski is a scholar working on Oncology, Immunology, Genetics, Molecular Biology and Biomedical Engineering, having authored 38 papers that have together received 4.0k indexed citations. Recurring topics across this work include CAR-T cell therapy research (33 papers), Immune Cell Function and Interaction (19 papers), T-cell and B-cell Immunology (11 papers), Immunotherapy and Immune Responses (10 papers), Virus-based gene therapy research (8 papers), Nanowire Synthesis and Applications (5 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Hepatitis B Virus Studies (2 papers). The work is most often cited by research in Oncology (3.5k citations), Immunology (1.7k citations), Genetics (1.0k citations), Biomedical Engineering (1.2k citations) and Hepatology (138 citations). Markus Chmielewski has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Hinrich Abken, Andreas Hombach, Gunter Rappl, Tobias Riët, Claudia Heuser, Gregory P. Adams, Rolf Kiessling, Felix Bohne, Ulrike Protzer and Thomas Blankenstein. Their work appears in journals such as Molecular Therapy, Frontiers in Immunology, Gastroenterology, OncoImmunology and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mio KitanoBreakdown of academic impact, for papers by Sid P. KerkarBreakdown of academic impact, for papers by Andreas HombachBreakdown of academic impact, for papers by Joseph A. FraiettaBreakdown of academic impact, for papers by Meng-Fen WuBreakdown of academic impact, for papers by David E. GilhamBreakdown of academic impact, for papers by Leonid CherkasskyBreakdown of academic impact, for papers by Andrew KaiserBreakdown of academic impact, for papers by April DurettBreakdown of academic impact, for papers by Dhanalakshmi Chinnasamy